The Clinical Efficacy and Safety of Gumiganghwal-Tang in Knee Osteoarthritis: A Phase II Randomized Double Blind Placebo Controlled Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chang, Sung Hae | - |
dc.contributor.author | Song, Yun-Kyung | - |
dc.contributor.author | Nah, Seong-Su | - |
dc.date.accessioned | 2021-08-11T13:43:59Z | - |
dc.date.available | 2021-08-11T13:43:59Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1741-427X | - |
dc.identifier.issn | 1741-4288 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/6837 | - |
dc.description.abstract | Background. Gumiganghwal-tang (GMGHT) is a traditional herbal medicine consisting of nine different herbs. GMGHT inhibits the mRNA expression and production of inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and TNF-beta on lipopolysaccharide-(LPS-) stimulated peritoneal macrophages in a dose-dependent manner. It is empirically used for the treatment of inflammatory disease, but there are few reports of clinical trials that investigate its efficacy and safety. The current study aimed to investigate the clinical efficacy and safety of GMGHT in patients with knee osteoarthritis (OA). Methods. This was a multicenter, two-armed, double-blinded, randomized, placebo controlled study of GMGHT over 6 weeks. Eligible patients who fulfilled theAmericanCollege of Rheumatology criteria for OA were randomized to receive eitherGMGHT or the placebo. Clinical assessments includedmeasurement of knee pain and function using theWesternOntario andMcMasterUniversities Osteoarthritis Index (WOMAC), patient global assessment (PGA), and knee pain scores every 2weeks. Results. Atotal of 128 patientswere enrolled (91.4% female; mean age, 58.7 +/- 8.1 years). At baseline, pain visual analogue score (VAS) was 67.2 +/- 1.4, resp. 71.3 +/- 1.6 (treatment, resp. placebo group, p= 0.84), and total WOMAC score was 55.2 +/- 1.6, resp. 55.6 +/- 1.5 (p = 0.84). After 6 weeks, the pain VAS was 43.0 +/- 2.5, resp. 61.6 +/- 2.5 (p < 0.01) and the totalWOMAC score was 34.1 +/- 2.4, resp. 46.9 +/- 1.8 (p < 0.01). No patients withdrew because of treatment emergent adverse events. Expected adverse events including dyspepsia, liver function abnormality, and lower extremity edemawere comparable between both groups. Conclusions. Treatment withGMGHTresulted in significant improvement in pain, function, and global assessment, and it was generally safe and well tolerated in patients with OA. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Oxford University Press | - |
dc.title | The Clinical Efficacy and Safety of Gumiganghwal-Tang in Knee Osteoarthritis: A Phase II Randomized Double Blind Placebo Controlled Study | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1155/2018/3165125 | - |
dc.identifier.scopusid | 2-s2.0-85057324675 | - |
dc.identifier.wosid | 000451134100001 | - |
dc.identifier.bibliographicCitation | Evidence-based Complementary and Alternative Medicine, v.2018 | - |
dc.citation.title | Evidence-based Complementary and Alternative Medicine | - |
dc.citation.volume | 2018 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Integrative & Complementary Medicine | - |
dc.relation.journalWebOfScienceCategory | Integrative & Complementary Medicine | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | INHIBITORS | - |
dc.subject.keywordPlus | TRIALS | - |
dc.subject.keywordAuthor | 의약학 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.